Almirall/Lilly lebrikizumab offers potential long-term management of atopic dermatitis
pharmaphorum
SEPTEMBER 16, 2022
Dr Jacob Thyssen, an expert on AD, and professor at the University of Copenhagen, dermatologist at Bispebjerg Hospital, as well as senior author of lebrikizumab’s ADvocate analyses, spoke to pharmaphorum soon after presenting the findings at The European Academy of Dermatology and Venerology (EADVC) on 8th September.
101 
Let's personalize your content